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Summary The relationship between the expression of nm23, a putative metastasis-suppressor gene and prognosis was determined for 88
patients with sarcomas. Immunohistochemistry using immunopurified anti-nm23 peptide antibodies was performed and the results of each
case graded according to the degree of staining. Univariate and multivariate analyses were carried out to determine the prognostic
significance of nm23 staining for sarcoma patients. Expression of nm23 was found to increase in line with metastatic potential in many cases
but this did not reach significance for the study as a whole. However, the possibility of nm23 loss occurring in association with metastasis
cannot be ruled out in some more aggressive sarcomas, as was demonstrated for six patients with low-scoring, unclassified and synovial
sarcomas that had metastasized. The time to metastasis was longer for patients with grade 3 sarcomas (50-75% of tumour cells staining)
than similar patients in other staining groups. These results suggest that expression of nm23 genes in sarcomas is variable and has no value
as a prognostic indicator for these mesenchymal tumours.
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Soft tissue sarcomas are rare tumours occurring at different sites of
the body and varying greatly in their degree of aggressiveness.
Although a number of prognostic factors are associated with the
metastatic potential of these tumours, e.g. tumour size, site, depth
and histological type, tumour grade remains to be the single most
reliable prognostic indicator (Russell et al, 1977; Hajdu, 1979;
Robinson et al, 1990). Approximately 60% of sarcomas are high
grade and approximately half of these will metastasize, predomi-
nately to the lung. To provide therapy appropriate to prognosis and
tumour responsiveness, precise diagnostic and predictive markers
would be an advantage. New functionally based tests are therefore
required to assist in the determination of the potential aggressive
nature of sarcomas and thus the value to the patient of any adju-
vant therapy.
nm23 is a putative metastasis-suppressor gene originally identi-
fied because of its down-regulation in highly metastatic variants of
a murine melanoma cell line (Steeg et al, 1988). The two tandemly
arranged nm23 genes NMEJ and NME2 code for the proteins
nm23H1 and nm23H2, which share sequence homology with
nucleoside diphosphate kinase (NDPK)A and (NDPK)B respec-
tively (Wallet et al, 1990; Gilles et al 1991; Stahl et al, 1991).
Although nm23 possesses enzyme activity, both its precise func-
tion and the mechanism by which it participates in anti-metastatic
protection is uncertain. Recent data have dissociated NDP kinase
activity both from levels of nm23 message and from any anti-
metastatic effects (MacDonald et al, 1993). Several biochemical
activities have been proposed for the nm23 proteins that could have
regulatory significance and these include: activation of G proteins,
homology with GAP proteins, inhibition of myeloid differentiation,
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signal transduction involving a reversible serine phosphorylation
and transcriptional regulation of genes including c-myc (Kimura
and Shimada, 1990;.Teng et al, 1991; Okabe-Kado et al, 1992;
McDonald et al, 1993; Postel et al, 1993; Urano et al, 1993).
Loss of heterozygosity and reduced expression of nm23 has
been associated with poor prognosis and increased incidence of
metastases in many epithelial tumours, such as those of colon,
breast, melanocytes and liver (Hennessy et al, 1991; Leone et al,
1991a; Nakayama et al, 1992; Royds et al, 1993, 1994). These
findings are supported by results from experimental studies and in
particular from transfections of nm23Hl into murine melanoma
and human breast carcinoma cell lines. The resultant constitutive
nm23 expression not only caused a reduction in the metastatic
potential of the cells but also altered their response to growth
factors (Steeg et al, 1988; Leone et al, 1991a, 1993a). However,
the inverse relationship between nm23 expression and metastatic
potential is by no means universal and other tumours, such as
those of the thyroid and lung, do not show an inverse correlation
(Higashiyama et al, 1992; Luo et al, 1993; Royds et al, 1994).
Moreover, in neuroblastoma, elevated levels of nm23 transcripts
along with amplification and mutation of the nm23Hl gene were
associated with advanced stages of the disease and poor patient
survival (Hailat et al, 1991; Leone et al, 1993b).
Thus, the relationship between nm23 and metastatic potential
may vary between different tumour types. Most studies to date have
focused on carcinomas and very little is known about the signifi-
cance ofnm23 in tumours of mesenchymal origin. A positive corre-
lation has been demonstrated, using Northern blotting, between
NDPK alpha (nm23H2) and metastatic ability in rat osteosarcomas
(Honoki et al, 1993). In a recent report on nm23 expression in
Ewing's sarcoma (Arye et al, 1995), nm23HlI/NDPK-A expression
was consistently high and nm23H2/NDPK-B expression, although
weaker and variable, was considered to be of no prognostic signifi-
cance for these aggressive and presumably neuroectodermal paedi-
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Figure 1 Low-power photomicrograph of a malignant fibrous
histiocytoma that metastasized, exemplifying grade 4 staining for nm23.
Magnification x 210
Figure 3 High-power photomicrograph of a rhabdomyosarcoma that
metastasized, exemplifying grade 1 staining for nm23. Magnification x 400
atric tumours. However, we are not aware of any previous study on
nm23 gene expression in a wide range of sarcomas and in adult
human sarcomas in particular. The present study was designed to
determine the relationship, if any, between nm23 gene expression,
tumour grade and metastasis in soft tissue sarcoma.
MATERIALS AND METHODS
Eighty-eight patients referred to The Royal Marsden Hospital,
London, with previously untreated soft tissue sarcoma were
entered into the study. These patients (aged 2-80 years) were
followed for a minimum of 3 years from the time of diagnosis or
until death. Tumours were assigned by one of us (CF) to one of
three grades (high, intermediate or low) either by tumour type or
according to a scoring system based upon the degree of necrosis,
pleomorphism, cellularity and mitotic activity. The following
tumours were all considered to be high grade: synovial sarcoma,
rhabdomyosarcoma, extraskeletal osteosarcoma, Ewing's and
peripheral neuroectodermal tumours. Primary histological diag-
nostic confirmation was by 'Trucut' or open excision biopsy.
Patients were divided into four groups according to tumour
......
Figure 2 High-power photomicrograph of a haemangiopericytoma,
exemplifying grade 4 staining for nm23. Magnification x 400
Figure 4 High-power photomicrograph of a high-grade malignant fibrous
histiocytoma that did not metastasize, exemplifying grade 3 staining for
nm23. Magnification x 400
grade and whether they had developed metastases. Patients with
high- and intermediate-grade tumours were grouped together as
their prognoses have been shown to be identical. Patients in two
groups had not developed metastases during at least 3 years
follow-up. These patients were subdivided according to whether
they had tumours of low or intermediate/high grade; the other two
groups represented patients who had developed metastases.
Group 1
Group 2
Group 3
Group 4
Low grade, no metastases
High grade, no metastases
High grade, metastases
Low grade, metastases
20
24
39
5
The commonest histological types were malignant fibrous histio-
cytoma (MFH) (21), unclassified (19), liposarcoma (14) and synovial
sarcoma (8). The remaining sarcomas were leiomyosarcoma (2),
rhabdomyosarcoma (2), osteosarcoma (1), chondrosarcoma (3),
haemangiopericytoma (1), Ewing's sarcoma (4), fibrosarcoma (5),
epitheioid (3) and neural sheath tumour (5). Tumours occurred in all
major sites - extremity (49), girdle (16), head and neck (10), trunk
(9) and retroperitoneum (4). The diagnosis of metastasis was made
clinically with or without further biopsy. Between one and three
British Journal of Cancer (1997) 75(8), 1195-1200 0 Cancer Research Campaign 1997
nm23 expression and prognosis in soft tissue sarcomas 1 197
Table 1 NM23 staining scores vs tumour grade
nm23 staining
Grade 1 2 3 4 Total
High 3 12 16 27 58
Intermediate 0 1 2 1 4
Low 0 3 11 12 26
Table 2 nm23 staining scores vs tumour site
nm23 staining
Site 1 2 3 4 Total
Girdle 2 4 8 2 16
Head and neck 0 1 3 6 10
Truncal 1 0 4 4 9
Extremity 0 11 12 26 49
Retroperitoneal 0 0 2 2 4
Table 3 nm23 staining scores vs tumour histology
nm23 staining
Histology 1 2 3 4 Total
MFH 0 4 11 6 21
Synovial sarcoma 1 0 2 5 8
Unclassified sarcoma 0 6 2 11 19
Liposarcoma 0 2 4 8 14
MNST 0 0 5 0 5
Ewing's sarcoma 1 1 1 1 4
Others 1 3 4 9 17
MNST, malignant neural sheath tumour.
blocks of formalin-fixed paraffin-embedded tissue were obtained
from the initial tumour specimen for each case. Sections (5 gm)
were cut, dewaxed and stained using a 1:200 dilution of an
immunopurified polyclonal antibody raised to the internal peptide
11 of nm23 (a gift from Dr P Steeg). After extensive washes in
phosphate-buffered saline (PBS), the bound antibody was detected
with a three-stage avidin-biotin-peroxidase complex technique
using diaminobenzidine hydrochloride (DAB) as chromogen
(Vector Laboratories, Peterborough, UK). Sections were lightly
counterstained with haematoxylin. Omission of the primary anti-
body was performed as a negative control. The sections were
graded from 1 to 4 according to the degree of staining, i.e. 1
(0-25%), 2 (25-50%), 3 (50-75%) and 4 (75-100%), of cells
strongly positive. In keeping with the principles established in our
studies on other tumours (Royds et al, 1993, 1994), each case with
multiple blocks was ascribed an overall score according to the
lowest nm23 staining score obtained. Univariate and multivariate
analyses were carried out to determine associations between
metastasis, recurrence, death, nm23 staining and other prognostic
factors.
Analysis was carried out separately for four of the specific
histological types MFH (n = 21), unclassified (n = 19), lipo-
sarcoma (n = 14) and synovial sarcoma (n = 8) for which the
numbers were sufficiently large.
Table 4 nm23 staining scores vs time to metastasis
Grade nm23
score
4
4
4
4
3
2
4
4
4
2
3
2
4
4
3
2
2
3
4
1
4
4
1
4
4
2
2
4
4
3
4
4
3
3
3
3
4
4
3
3
2
3
3
1
1
1
1
1
3
3
1
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Time to metastasis
(days)
0
29
98
118
121
126
141
164
174
179
195
203
206
209
213
217
252
256
283
350
382
382
406
416
419
428
443
450
450
456
526
547
549
617
629
666
667
672
687
707
748
869
1491
1844
RESULTS
The anti-nm23 antibody has been characterized previously and
shown to give two bands size 17 and 18 kb on Western blot
(Rosengard et al, 1989). Based on amino acid sequences, anti-
peptide 11 nm23 antiserum may detect both nm23Hl and
nm23H2. Staining for nm23 was predominately cytoplasmic but
nuclear staining was seen in some sections (Figures 1-4). Of the
88 patients in the study, 19 developed recurrent disease, 23 devel-
oped metastases and 38 died from their tumour. Tumour grade was
the only significant prognostic factor for survival or metastasis on
mulivariate analysis (relative risk of dying as a result of a high-
grade tumour = 8.55, P < 0.0001) (Table 1). However, of the 44
tumours that metastasized, five (11%) were low grade. No signifi-
cant association between tumour variables (type, site, size, grade),
patient variables (sex, age), length of survival or time to metastasis
and the degree of nm23 staining was seen (Tables 1-4 and Figure
5). However, it is interesting to note that the time to metastasis was
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One of the most significant findings was that nm23 score 3| sarcomas had a longer time to metastasis than any other staining
group. There was a longer mean time to metastasis of 671 days for
L ------------ group 3 sarcomas compared with a mean of 431 days for sarcomas
as a whole. In contrast, the nm23 group 4 tumours had a shorter
than average time to metastasis, irrespective of tumour type (mean
332 days, range 29-687 days). Loss of nm23, as inferred by
.__________________________________________ staining in less than 25% of cells (nm23 group 1), was accompa-
nied in all the three cases by a rapid development of metastasis.0 730 14~60 21'90 2920 3650
Sarcomas are a heterogeneous group of tumours and individualime to metastasis according to nm23 staining for high-grade sarcoma Sarcomas area iheereneous roupeof to nd individualtypes may behave differently with respect to nm23 expressioniraph showing the fraction of patients with high-grade sarcomas and metastatic potential. Analysis of the more common typesned metastasis free with time, for each of the nm23 staining (MFH, unclassified, liposarcoma and synovial sarcoma) revealed
that, for the more aggressive variants of unclassified and synovial
sarcomas, score 4 tumours showed high metastatic potential with
r patients with tumours in nm23 staining group 3 than 15 out of 16 score 4 tumours metastasizing. The MFH and liposar-
atients in other staining groups (Figure 5, relative risk of comas that metastasized were, however, more likely to have nm23
th a nm23 score 3 tumour = 0.64). Furthermore, the three score 3 (69% of the metastatic variants scored 3), with only 25%
with sarcomas that gave grade 1 staining (< 25% cells scoring 4. For the highly metastatic group of unclassified/synovial
all developed metastases within a short period of time sarcomas, all six tumours (100%) with an nm23 expression score
time of 266 days). of 1 or 2 metastasized. The comparable figure for score 1 and 2
;is of the individual types of sarcoma for the histological sarcomas as a whole is only 58%. This suggests that loss of nm23
,H (n = 21), unclassified (n = 19), liposarcoma (n = 14) expression has occurred in a few cases of these more aggressive,
vial sarcoma (n = 8) are shown in Table 3. Unclassified and usually highly staining, sarcomas and is associated with
vial sarcomas were highly metastatic with 24 out of 27 metastatic potential in every case. However, the significance of
these variants producing metastases. In contrast, only 12 this is not certain as the numbers are small.
(34%) of the MFH and liposarcomas were metastatic. The liposarcomas studied seemed to behave differently as 8 out
;on of these two groups, one of high, the other of low of 14 tumours were score 4, but only one of these was high grade
c potential, revealed that, although the average time to and metastasized. As there is an overall trend among sarcomas of
s was much shorter for the highly metastatic unclassi- increasing frequency of metastasis with increasing nm23 expres-
vial group (297 days compared with 667 days), this sion and as high expression (score 4) of nm23 accompanies
was negligible if only those tumours with staining metastatic potential in 60% of non-liposarcoma tumours, it does
4 were compared (355 days compared with 327 days). appear that human sarcomas behave similarly in the main to the rat
the difference was maintained in the score 3 tumours osteoblastoma and human neuroblastoma in which increased
compared with 819 days). The overall trend showed that expression is associated with aggressive disease and metastatic
an increased likelihood of developing metastasis with potential (Hailat et al, 1991; Honoki et al, 1993; Leone et al,
g nm23 scores, as seen from the fact that only 7% of 1993b). This is in contrast to many carcinomas in which loss of
sarcomas had an nm23 expression score of 1, 17.5% nm23 is associated with metastatic potential. However, the possi-
2, 29.5% had score 3 and rising to 45% for score 4. This bility that loss of nm23 may occur as a late event in the progres-
also shown by the individual histological sarcoma sion of some metastatic sarcomas cannot be ruled out. In fact, a
except that the less aggressive MFH and liposarcomas similar dichotomy has been reported for colorectal adenocarci-
fewer score 4 tumours with metastatic potential (see nomas with strong expression ofnm23H 1 and H2 being associated
The highly metastatic group (unclassified/synovial) with early stages of tumour progression and a loss of expression
5 out of 24 metastatic tumours that had lost nm23 expres- seen in more advanced disease (Martinez et al, 1995).
re 1 or 2). Because of the small numbers involved, the The finding that nm23 expression tends to increase as sarcomas
Lce of this is uncertain. become more aggressive is perhaps not surprising as nm23 expres-
sion has been shown to be proportional to proliferation, growth
;SION factor receptor levels and expression of the signal transducing
protein c-Ha-ras in many systems, including rat osteosarcomas
it here nm23 tumour expression for a large cohort of 88 (Kimura et al, 1990; Keim et al, 1992; Honoki et al, 1993; Mandai
ith a minimum of 3 years follow-up for each patient. The et al, 1994). Conversely, nm23 gene expression has been shown to
sarcomas demonstrated variable levels of expression of be down regulated along with c-myc expression by differentiating
gene product. However, most of the sarcomas studied and antiproliferative agents, such as vitamin D3 (Caligo et al,
Lg staining for nm23 in more than 50% of the cells with 1996). This close association of nm23 expression and proliferative
If of them having a staining score of 4 (40 out of 88). capacity appears to be lost in those cases in which growth factors
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are no longer required for cell cycle stimulation and control. This
has been shown for ovarian carcinomas and breast tumours and
cell lines that are oestrogen or progesterone receptor negative
(Bevilacqua et al, 1989; Stahl et al, 1991; Mandai et al, 1994).
Thus, it could be postulated that, when growth factor stimulation
of proliferation is high, it is accompanied by high expression of
nm23 possibly because of its function in signal transduction and
transcription of c-myc. This would explain why most at the score 4
metastatic sarcomas progressed very rapidly. In tumours in which
cell proliferation becomes uncoupled from growth factor stimula-
tion, then nm23 would no longer be necessary and its expression
may be lost. Such tumours would also carry a poor prognosis by
virtue of the fact that their proliferation is no longer limited by the
availability of growth factors. This could be the case for the
metastatic sarcomas that have low nm23 expression.
In summary, increases in nm23 gene expression in sarcomas
may signify a more active tumour which, if recurrent or metastatic,
will progress rapidly. Although some sarcomas may lose nm23
expression as they progress, the level of nm23 expression carries
no prognostic significance for sarcomas in general. Further work is
planned in our laboratory to determine the prognostic value of
nm23 loss in the more aggressive sarcoma variants and its possible
association with an uncoupling from growth factor control.
Additional evaluation of the differential effects of nm23H1 and H2
isoform expression in sarcomas and the possible loss of function of
the nm23 because of the presence of mutation is also required.
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